title: Quantification of 4 antidepressants and a metabolite by LC-MS for therapeutic drug monitoring.
abstract: A liquid chromatography method coupled to mass spectrometry was developed for the quantification of bupropion, its metabolite hydroxy-bupropion, moclobemide, reboxetine and trazodone in human plasma. The validation of the analytical procedure was assessed according to Société Française des Sciences et Techniques Pharmaceutiques and the latest Food and Drug Administration guidelines. The sample preparation was performed with 0.5 mL of plasma extracted on a cation-exchange solid phase 96-well plate. The separation was achieved in 14 min on a C18 XBridge column (2.1 mm×100 mm, 3.5 μm) using a 50 mM ammonium acetate pH 9/acetonitrile mobile phase in gradient mode. The compounds of interest were analysed in the single ion monitoring mode on a single quadrupole mass spectrometer working in positive electrospray ionisation mode. Two ions were selected per molecule to increase the number of identification points and to avoid as much as possible any false positives. Since selectivity is always a critical point for routine therapeutic drug monitoring, more than sixty common comedications for the psychiatric population were tested. For each analyte, the analytical procedure was validated to cover the common range of concentrations measured in plasma samples: 1-400 ng/mL for reboxetine and bupropion, 2-2000 ng/mL for hydroxy-bupropion, moclobemide, and trazodone. For all investigated compounds, reliable performance in terms of accuracy, precision, trueness, recovery, selectivity and stability was obtained. One year after its implementation in a routine process, this method demonstrated a high robustness with accurate values over the wide concentration range commonly observed among a psychiatric population.
authors.affiliation: Centre for Psychiatric Neuroscience, Department of Psychiatry, CHUV, University of Lausanne, Hospital of Cery, Prilly, Switzerland. Eva.Choong@chuv.ch
authors.forename: Eva
authors.initials: E
authors.lastname: Choong
authors.forename: Serge
authors.initials: S
authors.lastname: Rudaz
authors.forename: Astrid
authors.initials: A
authors.lastname: Kottelat
authors.forename: Sophie
authors.initials: S
authors.lastname: Haldemann
authors.forename: Davy
authors.initials: D
authors.lastname: Guillarme
authors.forename: Jean-Luc
authors.initials: JL
authors.lastname: Veuthey
authors.forename: Chin B
authors.initials: CB
authors.lastname: Eap
mesh_terms: D000928:Antidepressive Agents / Q000097:blood* / Q000302:isolation & purification; D016642:Bupropion / Q000031:analogs & derivatives / Q000097:blood / Q000302:isolation & purification; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D016903:Drug Monitoring / Q000379:methods*; D004355:Drug Stability; D006801:Humans; D020912:Moclobemide / Q000097:blood / Q000302:isolation & purification; D009025:Morpholines / Q000097:blood / Q000302:isolation & purification; D000077593:Reboxetine; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D052616:Solid Phase Extraction; D021241:Spectrometry, Mass, Electrospray Ionization / Q000379:methods*; D014196:Trazodone / Q000097:blood / Q000302:isolation & purification
chemical_list: D000928:Antidepressive Agents; D009025:Morpholines; D016642:Bupropion; D000077593:Reboxetine; D020912:Moclobemide; D014196:Trazodone